SCHEMBL29917985

SCHEMBL29917985

Cc1cc(C)c(Oc2nc(C(C)(C)C)ccc2C(N)=O)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NNMT P40261 2/20 0.38
▸ MITF O75030 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CCR6 P51684 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ F10 P00742 1/20 0.35
▸ CDK5 Q00535 2/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ CRHR1 P34998 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ TNF P01375 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ KLF5 Q13887 1/20 0.34
▸ CDK5R1 Q15078 1/20 0.34
▸ NOD1 Q9Y239 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17648477 1.00 NNMT (0.38) NNMTMITFALDH1A1LMNAMAPT
SCHEMBL19121101 0.91 IKBKB (0.35) NNMTMITFALDH1A1LMNAMAPT
SCHEMBL29917990 0.88 PDE4B (0.35) NNMTLMNAF10CRHR1CDK8
SCHEMBL17646572 0.88 MEN1 (0.38) ALDH1A1LMNASMN1; SMN2CRHR1KDM4E
SCHEMBL20350431 0.86 MAPT (0.37) ALDH1A1MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL23182985 0.85 F10 (0.38) LMNASMN1; SMN2F10CRHR1NPC1
SCHEMBL29917027 0.79 CRHR1 (0.34) ALDH1A1CDK5CRHR1IKBKBKDM4E
SCHEMBL29917505 0.79 FLT1 (0.47) ALDH1A1LMNASMN1; SMN2
SCHEMBL17648576 0.79 FLT1 (0.47) ALDH1A1LMNASMN1; SMN2
SCHEMBL19440563 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3798214-B1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2022-09-14 — — EP claimed
Send feedback